Skip to Content
Author: The BCW

Leave a Comment

Regeneron Starts First Human Clinical Trials on COVID-19 “Cocktail”

http://thebcw.org/wp-content/uploads/2020/06/regeneron-1200×600-1.jpg

“REGN-COV2 could have a major impact on public health by slowing spread of the virus and providing a needed treatment for those already sick – and could be available much sooner than a vaccine,” said George D. Yancopoulos, co-founder, president and chief scientific officer of Regeneron.

“The antibody cocktail approach may also have long-term utility for elderly and immuno-compromised patients, who often do not respond well to vaccines. Ultimately, the world needs multiple solutions for COVID-19, and the innovative biopharma industry is collectively working hard to help as many people as possible with a variety of complementary approaches,” he added.

Marsha Gordon, President and CEO of the Business Council of Westchester, congratulated Regeneron on the groundbreaking announcement.

“If anyone can come up with a successful treatment for COVID-19, it is the great minds at Regeneron,’’ said Gordon. “We are so proud to have a worldwide leader that is giving us hope for treatment of this virus right here in Westchester.”

The cocktail consists of two antibodies that are produced in mice that have been genetically modified to have a human immune system. The antibodies being tested to fight COVID-19 are the same as if they had been produced in a human. The two antibodies bind to a protein that the virus uses to attack human cells and block it.

Four separate populations will be studied during the clinical trial. They are: hospitalized COVID-19 patients; nonhospitalized COVID-19 patients who show symptoms of the virus; uninfected people in groups that are at high-risk of exposure such as health care workers or first responders; and uninfected people with close exposure to a COVID-19 patient such as the patient’s spouse.

Trial investigator, Dr. Suraj Saggar, chief of infectious disease at Holy Name Medical Center in Teaneck, New Jersey, said, “Over the last long months, we have learned that repurposing existing medicines unfortunately does not offer a broadly effective solution for COVID-19. For this reason, we need to investigate custom-designed approaches like REGN-COV2. The first studies will evaluate if REGN-COV2 can improve disease outcomes in both hospitalized and non-hospitalized patients with COVID-19.”

READ MORE

Similar News Items

The Business Council of Westchester released its 2024 Legislative Agenda and called on state lawmakers to embrace policies that support a sustainable economy and job creation. The BCW produces the Annual Legislative Agenda each year for federal, state and local representatives on behalf of the business community. Among the recommendations in its 44-page report, the […]

Read Article

The Business Council of Westchester is among 43 business organizations representing tens of thousands of businesses of all sectors and sizes across New York urging the Senate and Assembly to allocate funding in the Fiscal Year 2025 budget to address the unemployment insurance debt; as well as support the Governor’s proposals to sunset the state’s […]

Read Article

Congratulations to the Burn Center at Westchester Medical Center on being verified by the American Burn Association (ABA) as an Adult and Pediatric Burn Center. The verification was made after a rigorous and thorough review of Westchester Medical Center’s burn care program. With this verification, BCW Member Westchester Medical Center is now home to the […]

Read Article

Become A Member

Join the county’s largest and most influential business organization today.

JOIN NOW!
The Business Council of Westchester is committed to helping businesses market, learn, advocate, and grow. Over 80 events and programs are offered every year, giving our members ample opportunity to connect and meet with businesses representatives in the Westchester community and beyond.
Back to top